Eisai

Lecanemab named one of the world's best inventions in 2023 by TIME

Retrieved on: 
Tuesday, October 24, 2023
Risk, Aneurysm, Vomiting, Cerebral edema, Focal neurologic signs, Incidence, Dementia, Nausea, Disease, Intraparenchymal hemorrhage, Intracerebral hemorrhage, CET, Chills, AI, Paracetamol, Hypersensitivity, Memory, Lecanemab, Vascular malformation, MRI, Excipient, Neuroimaging, Fatal, Thought, Dizziness, Aspirin, Edema, Anticoagulant, Cerebral amyloid angiopathy, Magnetic resonance imaging, Patient, Bronchospasm, Alzheimer's disease, Anaphylaxis, Genetic testing, TIME, ARIA, Arthralgia, Research, Eisai, Fever, Hypotension, Amyloid, Headache, Siderosis, Behavior, Invention, Observation, Hypertension, Confusion, Seizure, Angioedema, Status epilepticus, Tissue plasminogen activator, Pharmaceutical industry, Lace, Medical imaging, Copper

"It is a great honor and tremendous recognition that lecanemab is included in TIME's list of the world's best inventions this year.

Key Points: 
  • "It is a great honor and tremendous recognition that lecanemab is included in TIME's list of the world's best inventions this year.
  • TIME's annual list of the best inventions includes "200 extraordinary innovations changing lives."
  • The information was released for public disclosure, through the agency of the contact persons below, on October 24, 2023, at 4.50 p.m. CET.
  • ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events rarely can occur.

X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors

Retrieved on: 
Wednesday, October 18, 2023
Rare, Eisai, Senior, Immune system, Marketing, Amgen, Retirement, Roche, Florida State University, Alexion Pharmaceuticals, Pharmaceutical industry, Management

BOSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the appointment of R. Keith Woods as an independent director to the company’s Board of Directors.

Key Points: 
  • BOSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the appointment of R. Keith Woods as an independent director to the company’s Board of Directors.
  • “We are thrilled to welcome Keith to the X4 Board of Directors,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.
  • Following his retirement from argenx, Mr. Woods continues to serve as an advisor to the argenx Board of Directors.
  • Mr. Woods commented on his appointment: “It is a privilege to join the X4 Board at this exciting time, given the recent U.S. regulatory submission of the company’s first drug candidate and potential upcoming U.S. commercial launch.

Infusion Associates Administers Eisai and Biogen's New Alzheimer's Medication at Their Outpatient Infusion Center in Troy, Mich.

Retrieved on: 
Thursday, October 19, 2023
Patient, Insurance, MRI, Food and Drug Administration, Eisai, Myenteric plexus, Love, Alzheimer's Association, CMS, Medical device, Medical imaging, Alzheimer's disease, Lecanemab, Biogen

Infusion Associates' expert clinical teams have been caring for patients with chronic neurological conditions through infusion and injection treatments for over 20 years.

Key Points: 
  • Infusion Associates' expert clinical teams have been caring for patients with chronic neurological conditions through infusion and injection treatments for over 20 years.
  • "We are proud to be able to offer this innovative treatment at Infusion Associates and will continue to advocate for new therapies for our patients."
  • The new infusion treatment, developed by drug manufacturers Eisai and Biogen , is the first disease-modifying treatment for early-stage Alzheimer's and mild cognitive impairment to receive full regulatory approval.
  • Visit Infusion Associates' Leqembi medication page for more information: https://infusionassociates.com/infusion-therapy/medications/leqembi/ .

American Liver Foundation Hosts Free Liver Cancer Conference for Patients and Families

Retrieved on: 
Wednesday, October 18, 2023
Knowledge, ALF, DO, Genomics, AstraZeneca, NCI, University of Florida Health, MPH, University of Wisconsin–Madison, Health, Education, MD, California Pacific Medical Center, Conference, MBA, Research, American Liver Foundation, Yale University, Parul, Liver cancer, Doctor of Public Health, Caregiver, Environmental epidemiology, Rush University Medical Center, National Cancer Institute, University, NIH, Mindfulness, Memorial Sloan Kettering Cancer Center, Patient, Houston Methodist Hospital, Bangladesh Technical Education Board, MS, Dietary supplement, Pharmaceutical industry, Eisai

FAIRFIELD, N.J., Oct. 18, 2023 /PRNewswire/ -- October is Liver Cancer Awareness Month and American Liver Foundation is pleased to host The Educated Patient: A Liver Cancer Conference Presented on October 21stf from 11AM to 2PM ET. Now in its fourth year, this one-day virtual education program is created especially for liver cancer patients, family members or caregivers who can register for free. The conference offers presentations, workshops and opportunities for engagement with leading medical experts, researchers and others knowledgeable about the issues most relevant to those dealing with liver cancer.

Key Points: 
  • The one-day virtual event brings together patients, caregivers, leading medical experts and researchers
    FAIRFIELD, N.J., Oct. 18, 2023 /PRNewswire/ -- October is Liver Cancer Awareness Month and American Liver Foundation is pleased to host The Educated Patient: A Liver Cancer Conference Presented on October 21stf from 11AM to 2PM ET.
  • Now in its fourth year, this one-day virtual education program is created especially for liver cancer patients, family members or caregivers who can register for free .
  • ALF's free virtual Liver Cancer Conference is October 21st.
  • She added, "We hope that this year's conference will provide patients and their families with new knowledge, resources, and support."

Eisai to Present New Data from LEQEMBI (Lecanemab-Irmb) Phase 3 Clarity Ad Study and Other Alzheimer's Disease Pipeline Research at The Clinical Trials on Alzheimer's Disease (CTAD) Conference

Retrieved on: 
Monday, October 16, 2023
Senior, PAM, Donanemab, Lecanemab, Death, Amyloid, Brain, Clinical trial, PET, Disease, Clinical research, Neurology, Clarity, EDT, AD, Tropomyosin receptor kinase A, Research, Amyloid beta, Pharmaceutical industry, Medical imaging, MD, MPH, Alzheimer's disease, Eisai

The conference will be held in Boston, Massachusetts, United States and virtually from October 24 to 27, 2023.

Key Points: 
  • The conference will be held in Boston, Massachusetts, United States and virtually from October 24 to 27, 2023.
  • At the conference, Eisai will present data and research in five oral and ten poster presentations.
  • "We look forward to sharing the new LEQEMBI low-tau subgroup data and subcutaneous data at CTAD 2023."
  • The full list of presentations about Eisai assets and research, click the link: www.eisai.com/news/2023/news202365.html

Eisai to Present Research from Oncology Portfolio and Pipeline at ESMO Congress 2023

Retrieved on: 
Wednesday, October 11, 2023
MSD, Congress, Senior, Hepatocellular carcinoma, Abstract, Pembrolizumab, Trial of the century, Bristol Myers Squibb, Merck & Co., Safety, Lung cancer, FR, Endometrial cancer, LEAP, Cancer, Fallopian tube cancer, Patient, FDA, ESMO, Oncology, Ovarian cancer, Meta-analysis, Merck, Research, Science, Lenvatinib, European Society for Medical Oncology, ADC, Pharmaceutical industry, Eisai

We also look forward to sharing data for lenvatinib and from our pipeline, as well as engaging in critical scientific exchange with the community in service of moving oncology research forward."

Key Points: 
  • We also look forward to sharing data for lenvatinib and from our pipeline, as well as engaging in critical scientific exchange with the community in service of moving oncology research forward."
  • A network meta-analysis of lenvatinib versus key comparators as first-line treatment for patients with unresectable hepatocellular carcinoma will also be presented during a poster session (Presentation: #1007P).
  • These abstracts will be made available via the ESMO website on Monday, October 16, 2023, at 12:05 AM CEST.
  • In June 2021, Eisai and Bristol Myers Squibb entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of FZEC.

Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease

Retrieved on: 
Tuesday, October 10, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, MSD, NYSE, Abstract, Breast cancer, Brentuximab vedotin, INT, Trastuzumab, RCC, Survival, Endometrial cancer, PEM, NRG, ESMO, Merck & Co., Webcast, Belzutifan, European Society for Medical Oncology, ADC, Research, TUC, KRAS, Lung cancer, RAS, AstraZeneca, EC, Adenocarcinoma, Head, TNBC, MRK, Pembrolizumab, Everolimus, CRC, Cancer, Olaparib, EFS, Quality of life (healthcare), SWOG, Congress, LBA32, LBA21, PBO, Chemoradiotherapy, CP, Safety, MBC, Patient, Pharmaceutical industry, Birth control, Medical imaging, Animal feed, Vaccine, Tras, Merck, NSCLC, Eisai

The event will take place virtually and will be accessible via webcast.

Key Points: 
  • The event will take place virtually and will be accessible via webcast.
  • Safety and preliminary efficacy of the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC.
  • Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIB-IV melanoma from SWOG S1801.
  • mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response.

Eisai: Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of KAN Research Institute, Inc.

Retrieved on: 
Wednesday, October 4, 2023
Executive, Effective date, Tripura Merger Agreement, Disclosure, Research, Brain, Antibody, Organization, Acquisition, Patient, Deep, Companies Act, Drug discovery, Biology, R, Companies Act 2006, Disease, Pharmaceutical industry, Airline, Security (finance), Mergers and acquisitions, Eisai

In October 2022, the Company group's research and development (R&D) organization transitioned to the Deep Human Biology Learning (DHBL) drug discovery and development.

Key Points: 
  • In October 2022, the Company group's research and development (R&D) organization transitioned to the Deep Human Biology Learning (DHBL) drug discovery and development.
  • Through this merger, Eisai will further deepen it's understanding of human biology, while KAN Research Institute will continue to contribute tothe innovative creation as a major base of drug discovery research of the Company.
  • The Merger is an absorption-type merger with the Company as the surviving company and KAN Research Institute as the absorbed company which dissolves as a result of the Merger.
  • Since the Company holds all shares in KAN Research Institute, no consideration will be provided upon the Merger.

Eisai Launches New "Innovation" Page on Corporate Website

Retrieved on: 
Thursday, September 28, 2023
Anxiety, Policy, Venture capital, Open innovation, Record, Innovation, Digital technology, Dementia, Patient, Deep, Drug discovery, Ecosystem, R, Corporate venture capital, Health, Management, Eisai

TOKYO, Sept 28, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched a new "Innovation" page on its corporate website.

Key Points: 
  • TOKYO, Sept 28, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched a new "Innovation" page on its corporate website.
  • The "Innovation" page is comprised of four sections: "Research & Development (R&D)," "Ecosystem," "Open Innovation," and "Corporate Venture Capital," which are the core of Eisai's innovation creation.
  • On the newly established "Innovation" page, Eisai has enhanced information on policies, characteristics, and examples of initiatives for innovation creation aimed at realizing its corporate concept.
  • Eisai will continue to disclose information in a proactive and easy-to-understand manner through our corporate website and communicate with all of our stakeholders to help them understand our corporate concept and business activities.

Tokio Marine Nichido and Eisai Co-Develop Industry's First "Dementia Care Support Insurance"

Retrieved on: 
Thursday, September 28, 2023
Insurance, Male, Alzheimer's disease, Smartphone, Policy, Pathology, Tokio Marine Nichido, Hope, PET, Attention, Dementia, Organization, Eisai, Patient, Self-assessment, Diagnosis, Ageing, Memory, Disease, Residential care

TOKYO, Sept 28, 2023 - (JCN Newswire) - Tokio Marine & Nichido Fire Insurance Co., Ltd. and Eisai Co., Ltd. announced that they have co-developed "Dementia Care Support Insurance" to financially support early detection and early treatment for dementia as a part of their business alliance for the realization of a Dementia Inclusive Society.

Key Points: 
  • TOKYO, Sept 28, 2023 - (JCN Newswire) - Tokio Marine & Nichido Fire Insurance Co., Ltd. and Eisai Co., Ltd. announced that they have co-developed "Dementia Care Support Insurance" to financially support early detection and early treatment for dementia as a part of their business alliance for the realization of a Dementia Inclusive Society.
  • Amid such circumstances, the two companies co-developed a new insurance product, "Dementia Care Support Insurance" to financially support early detection and early treatment of the disease, with the expertise Tokio Marine Nichido has developed through dealing with insurance products and related services and Eisai's extensive experience in the field of dementia.
  • Since these tests and treatments require a certain level of out-of-pocket expenses, the following coverage will be provided for financial support.
  • Tokio Marine Nichido and Eisai will further promote efforts to resolve various social challenges by expanding our network through collaboration with various companies and organizations, to realize a Dementia Inclusive Society.